Expansion of circulating tumor-specific T cells after treatment suggested systemic antitumor immunity
The anti-PD1 immunotherapy nivolumab (Opdivo) given prior to surgical resection of stage 1-3 non-small cell lung cancer (NSCLC) was safe and resulted in major pathological responses in 45 percent of the patients, according ...
Apr 16, 2018
0
2